Evidence map›Paper›PMID 37816816›Full record

Observational studyEuropean journal of clinical pharmacology2023

Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data.

Majdoleen Alalawneh, Ousama Rachid, Ibtihal Abdallah, Ahmed Mahfouz, Hazem Elewa, Mohammed Ibn-Mas'ud Danjuma, Asmaa Ezzeldin Mohamed, Ahmed Awaisu

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in European journal of clinical pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Majdoleen AlalawnehCollege of Pharmacy, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar.ORCID http://orcid.org/0000-0002-6597-1647
Ousama RachidCollege of Pharmacy, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar.ORCID http://orcid.org/0000-0002-2364-3848
Ibtihal AbdallahClinical Pharmacy Services, Hamad General Hospital, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar.ORCID http://orcid.org/0000-0001-7151-6280
Ahmed MahfouzPharmacy Department, Heart Hospital, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar.ORCID http://orcid.org/0000-0002-6253-1670
Hazem ElewaCollege of Pharmacy, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar.ORCID http://orcid.org/0000-0003-1594-1199
Mohammed Ibn-Mas'ud DanjumaDepartment of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar.ORCID http://orcid.org/0000-0003-2198-5278
Asmaa Ezzeldin MohamedClinical Pharmacy Services, Hamad General Hospital, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar.
Ahmed AwaisuCollege of Pharmacy, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar. aawaisu@qu.edu.qa.ORCID http://orcid.org/0000-0002-9029-8925
Qatar University · QAHamad General Hospital · QAHamad Medical Corporation · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate real-world prescribing trends and clinical outcomes based on body mass index (BMI) categorization in patients who received rivaroxaban therapy.

methodsThis was a retrospective cohort study involving all patients who received rivaroxaban therapy across all Hamad Medical Corporation (HMC) hospitals from 2015 to 2020.

resultsThe number of patients initiated on rivaroxaban therapy significantly increased from 152 (3.3%) in 2015 to 1342 (28.9%) in 2020 (p <0.001). Within BMI categories, a similar increasing trend was observed in underweight, normal, and overweight patients, while from 2018 to 2020, there was a decreasing trend in rivaroxaban prescribing in all obese classes. The prevalence rate of all-cause mortality differed significantly between the BMI groups, with the highest mortality being among morbidly obese patients (BMI ≥ 40 kg/m

conclusionsRivaroxaban prescribing has significantly increased over the years across general population, with a noticeable decline in obese population during the last few years (from 2018 onwards). Furthermore, an appreciable association was evident between all-cause mortality and BMI of these patients.

Indexed as

Atrial FibrillationObesity, MorbidAnticoagulantsBody Mass IndexHumansOverweightRetrospective StudiesRivaroxabanThinnessAnticoagulantsRivaroxabanBody mass indexClinical outcomesDirect oral anticoagulantsObeseRivaroxaban

Identifiers

PMID37816816
PMCPMC10663176
OpenAlexW4387492213

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.